{"id":"W3107453141","doi":"10.1136/esmoopen-2020-001079","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Sunitinib; Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Gastroenterology; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003264888,0.001018187,0.002676405,0.0002441015,0.0003737922,0.001263636,0.0008383448,0.001175178,0.002880758],"category_scores_gemma":[0.002502513,0.0003894831,0.00304018,0.0003496345,0.0005073758,0.0008804423,0.0004887272,0.002440488,0.0004199847],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00102283,"about_ca_system_score_gemma":0.001065446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008799214,"about_ca_topic_score_gemma":0.00259775,"domain_scores_codex":[0.9989286,0.0007157592,0.00005126971,0.0001217905,0.00007961578,0.000102835],"domain_scores_gemma":[0.9986095,0.0003099343,0.0005394273,0.0001336824,0.00007654231,0.0003308257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9629134,0.002128272,0.003414289,0.0008202734,0.003700942,0.00004654675,0.00004771369,0.001227117,0.001556161,0.00009457027,0.001488588,0.02256215],"study_design_scores_gemma":[0.8730392,0.0928949,0.02232323,0.0001678179,0.00507044,0.0002357943,0.00004196781,0.001677312,0.0009510905,0.0004239795,0.003132256,0.00004196188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840488,0.01013331,0.0003941352,0.0007260607,0.000406558,0.001021085,0.001317819,0.00007209086,0.001880053],"genre_scores_gemma":[0.991184,0.002254457,0.0005395445,0.0007980844,0.0003277816,0.00114157,0.001910233,0.00001805469,0.001826337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003264888,"threshold_uncertainty_score":0.01726657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.086461553476601,"score_gpt":0.333877590462352,"score_spread":0.247416036985751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}